Presentation is loading. Please wait.

Presentation is loading. Please wait.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small.

Published byCameron Bond Modified over 8 years ago

Similar presentations

Presentation on theme: "U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small."— Presentation transcript:

1 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small Molecules (…and other aspects of translational research via NINDS) March 4, 2016 Jill Morris PhD jill.morris@nih.gov

2 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke 2 Translational Funding Opportunities Anticonvulsant Screening Program (ASP) Biotechnology Products and Biologics - CREATE Bio Small Business Program: SBIR & STTR Small Molecules – Blue Print Neurotherapeutics (BPN) Countermeasures Against Chemical Threats (CounterACT) Devices - CREATE Device Early Translation - IGNITE IGNITE: Innovation Grants to Nurture Initial Translational Efforts CREATE: Cooperative Research to Enable and Advance Translational Enterprises Discovery Preclinical Development Small Clinical Trials

3 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke “Discovery” Assay development Proof of concept in vitro and/or in vivo Lead optimization and candidate selection Pre-clinical Development Toxicology studies Scalable process development (gram to kg) Good Manufacturing Practice (GMP) drug manufacture “Small” Trial Only as part of certain programs with associated pre-clinical components 3 Discovery Preclinical Development Small Clinical Trials The Office of Translational Research

4 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Innovation Grants to Nurture Initial Translational Efforts (IGNITE) –IGNITE Allows Investigative Teams to meet the entry criteria for the CREATE or Blue Print Neurotherapeutics (BPN) Program –Upon Completion of IGNITE the Investigative Team will have: appropriate Pharmacodynamic markers/models (RFA-NS-16-013)RFA-NS-16-013 a well-validated Assay (PAR-15-070):PAR-15-070 Well-characterized early-stage Agents suitable for Optimization (PAR-15-071)PAR-15-071 4 http://www.ninds.nih.gov/funding/IGNITE Amir Tamiz, PhD amir.tamiz@nih.gov

5 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Entry Criteria: –Translational rationale for the proposed model system/or pharmacodynamics marker and evidence of value for drug development End Goal: –Improved animal models, human tissue ex vivo systems, or endpoints for translational efforts Mary Ann Pelleymounter mary.pelleymounter@nih.gov RFA-NS-16-013 RFA-NS-16-013 Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) 5 Innovation Grants to Nurture Initial Translational Efforts (IGNITE)

6 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Two Phases in Each Grant 6 Execution Phase R33 R21 R33 Budget per year< $0.25M DC/year Duration No more than 2 years (three total) Budget total (R21/R33) 0.75M for Entire 3 Year Period Planning/Development Phase  Meet Milestones IGNITE RFA 16-013 (Models and Markers)

7 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke –Entry Criteria: Rationally selected assay(s) and therapeutic agents –R21 phase initial development, refinement, and validation of assays –R33 phase iterative screening of potential therapeutic agents, further preparation and characterization characterization of promising therapeutic agents from the screen –End Goal: Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled 7 IGNITE PAR-15-070 (Assays and Agents) PAR-15-070 PAR-15-070 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)

8 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke –Entry Criteria: A validated/characterized animal model and pharmacodynamic measure(s) A testing protocol and Therapeutic agent(s) to test –R21 Phase: –Preparation, characterization of tx agent, dosage forms –Confirm that target is reached –R33 Phase: –Execution of the PD and/or in vivo efficacy studies –Target Engagement –End Goal: Well-characterized early-stage agents suitable for optimization 8 IGNITE PAR-15-071 (Pharmcodynamics, Efficacy) PAR-15-071 PAR-15-071 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)

9 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke IGNITE PARs (Assay-Target and Pharmacodynamics) Two Phases in Each Grant 9 Execution Phase R33 R21 R33 Budget per year< $0.25M/per year< $0.25M/year Duration No more than 2 years (three total) Budget total (R21/R33) <0.75M for Entire 3 Year Period Planning/Development Phase  Meet Milestones

10 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke 10 Hao Wang, PhD Hao.wang2@nih.gov

11 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke CREATE PROGRAM COMPARISON Discovery Track U01 (PAR-14-286) Development Track Uh2/UH3 (PAR-14-288) PurposeOptimization of Therapeutic Leads IND-Enabling and Early phase clinical trials End GoalsCharacterize and select a candidate with: stability, bioavailability, in vivo efficacy and/or target engagement An IND application submitted to the FDA. MechanismU01 (4 years)-milestonesUH2/UH3 (5 years)-milestones Funds Available <$500K DC/year<$1M DC/year for 2 years (UH2) <$1.5M DC/year (UH3) 11

12 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Optimization in Preparation for Development of Biotechnology Products and Biologics (U01) (PAR-14-286)PAR-14-286 Entry –Lead(s) show in vivo efficacy and/or target engagement –Lead(s) have been sufficiently characterized –Well characterized in vitro and in vivo assays exist Required end goals-completion of: –Optimization: structure, selectivity, stability, manufacturability, etc.(quantitative) –Candidate characterization: dose, time and duration of treatment –pharmacokinetics/bioavailability at the relevant site of action –pharmacodynamics –Feasibility for production and reproducible production of the candidate 12 Discovery Track

13 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Preclinical and Early-phase Clinical Development for Biotechnology Products and Biologics (UH2/UH3) (PAR-14-288)PAR-14-288 Entry (same as end goals of “Discovery Track”) –Optimization: structure, selectivity, stability, manufacturability, etc. –Candidate characterization: dose, time and duration of treatment –pharmacokinetics/bioavailability at the relevant site of action, and pharmacokinetics –pharmacodynamics –Feasibility for production and reproducible production of the candidate End Goal –IND –(Small clinical trial-optional) 13 Development Track

14 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Neuroscience Blueprint (NIH) Includes: –Office of the Director (OD) –15 Institutes/Centers with a Neuroscience Mission BRAIN Initiative –Cells, Circuits (Imaging, Technology) Grand Challenges –Human Connectome Project Map connections in the Human brain –Pain Consortium –Blueprint Neurotherapeutics Program 14 Blueprint Neurotherapeutics Network

15 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke 15 Amir Tamiz, PhD Program Director amir.tamiz@nih.gov Combines; NIH, Academic, Industry Expertise Modality: Small Molecule Discovery: Hit-to-lead and lead optimization Development: Formulation, scale up and manufacture, IND-enabling studies, and first-in-man clinical trials End Goals Discovery: Characterize and select a preclinical candidate Development: Complete IND-enabling studies file an IND Complete first-in-human trial Advance projects for “hand-off” http://neuroscienceblueprint.nih.gov/ Blueprint Neurotherapeutics Network

16 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke –Funding for work in Your Lab-assays, models –Access to NIH-funded contract research organizations (CROs) –Access to consultants-drug discovery and development –Your institution gets assignment of the intellectual property rights to compounds discovered and developed within the program 16 Blueprint Neurotherapeutics Network

17 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke 17 Blueprint Neurotherapeutics Network (BPN)

18 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke A Few Final Points –Start with your end goal in mind, and “work backwards” –Team approach is essential –Contact Program Directors “early” –Use Multiple approaches in order to accomplish goals “Parent” R01, OTR mechanisms, advocacy, industry –Check out the “Decision Tree”; it will walk you through to find which program may be the best fit http://www.ninds.nih.gov/funding/areas/translational_research/in dex.htmhttp://www.ninds.nih.gov/funding/areas/translational_research/in dex.htm http://www.ninds.nih.gov/otr 18

Download ppt "U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small."

Similar presentations

The Drug Discovery Process

The Drug Discovery Process
David M. Pollock Medical College of Georgia Discovery-Academia.

David M. Pollock Medical College of Georgia Discovery-Academia.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Dr. Kumud More ICRI, Mumbai 15/04/10

Dr. Kumud More ICRI, Mumbai 15/04/10
Challenges in new drug discovery in South Asia

Challenges in new drug discovery in South Asia
An Academic Model to Bridge the Valley of Death April 17, 2009 Scott Weir, PharmD, PhD Institute for Advancing Medical Innovation University of Kansas.

An Academic Model to Bridge the Valley of Death April 17, 2009 Scott Weir, PharmD, PhD Institute for Advancing Medical Innovation University of Kansas.
?? Collaborations for hypothermia research ?? Target disorder Different technologies Treatment protocols Basic/translational/clinical.

?? Collaborations for hypothermia research ?? Target disorder Different technologies Treatment protocols Basic/translational/clinical.
Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.

Optimization of Preclinical Animal Models Steven Perrin, PhD CEO, CSO ALS Therapy Development Institute.
EXAMPLE OF DRUG DEVELOPMENT. Objectives of preclinical tests Preclinical tests helps to  Evaluate its toxicity  Assess its effectiveness  Propose a.

EXAMPLE OF DRUG DEVELOPMENT. Objectives of preclinical tests Preclinical tests helps to  Evaluate its toxicity  Assess its effectiveness  Propose a.
Establishing Preclinical Development Operations in China Ming Guo, Ph.D. VP Pharmaceutical Sciences & Manufacturing SABPA Pacific Forum Nov. 4, 2006.

Establishing Preclinical Development Operations in China Ming Guo, Ph.D. VP Pharmaceutical Sciences & Manufacturing SABPA Pacific Forum Nov. 4, 2006.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Nanotechnology in Drug Discovery- Development and Delivery

Nanotechnology in Drug Discovery- Development and Delivery
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.

Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.

Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.
Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Similar presentations

Ads by Google